Upstream vs deferred administration of small-molecule glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction - Insights from randomized clinical trials

Circulation Journal

Volumn 74, Issue 8, 2010, Pages 1617-1624

  Dong, Lili ^a   Zhang, Feng ^a   Shu, Xianhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Eptifbatide; Myocardial infarction; Percutaneous coronary intervention; Tirofban

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; THERAPY DELAY; TREATMENT RESPONSE; VASCULAR PATENCY;

ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77955084308     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0050     Document Type: Article

References (42)

1. Petronio AS, Rovai D, Musumeci G, Baglini R, Nardi C, Limbruno U, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J 2003; 24: 67-76.
2. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-1903.
3. Antoniucci D, Migliorini A, Parodi G, Valenti R, Rodriguez A, Hempel A, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: A prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004; 109: 1704-1706.
4. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analy-sis of randomized trials. JAMA 2005; 293: 1759-1765.
5. Nakagawa Y, Nobuyoshi M, Yamaguchi T, Meguro T, Yokoi H, Kimura T, et al. Effcacy of abciximab for patients undergoing balloon angioplasty: Data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT). Circ J 2009; 73: 145-151.
6. Wu TG, Zhao Q, Huang WG, Wei JR, Chen SW, Zhao J, et al. Effect of intracoronary tirofban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ J 2008; 72: 1605-1609.
7. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
8. Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, American Heart Association, Antman EM, Hand M, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 210-247.
9. De Luca G, Ucci G, Cassetti E, Marino P. Benefts from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A meta-analysis. J Am Coll Cardiol 2009; 53: 1668-1673.
10. Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: A meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Intervent 2009; 2: 230-236.
11. Dong L, Zhang F, Shu X. Early administration of small-molecule glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention for ST-elevation myocardial infarction: Insights from randomized clinical trails. J Cardiovasc Pharmacol Ther 2010; 15: 135-144.
12. Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofban before primary angioplasty improves angiographic outcomes: Results of the TIrofban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003; 107: 1497-1501.
13. Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr, Dua V, Garringer J, et al. Effect of tirofban before primary angioplasty on initial coronary fow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003; 92: 977-980.
14. van't Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: Results of the ongoing tiro-fban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004; 25: 837-846.
15. Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, et al. Early eptifbatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: Results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 2005; 26: 1971-1977.
16. Emre A, Ucer E, Yesilcimen K, Bilsel T, Oz D, Sayar N, et al. Impact of early tirofban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting. Cardiology 2006; 106: 264-269.
17. Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, et al. Early initiation of eptifbatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 2006; 152: 668-675.
18. Xu L, Yang XC, Wang LF, Ge YG, Wang HS, Li WM, et al. Effect of pre-angiography use of tirofban in patients with acute ST-eleva-tion myocardial infarction treated by primary percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34: 983-986.
19. Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, et al. Clinical benefts of adjunctive tirofban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis 2008; 19: 271-277.
20. Van't Hof AW, Ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, et al. Prehospital initiation of tirofban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial. Lancet 2008; 372: 537-546.
21. Bonnefoy E, On behalf of AGIR2 investigators. Comparison of pre-hospital or cath lab administration of high dose tirofban in patients undergoing primary angioplasty: The AGIR2 Study. Presented at ACC 2009 in Orlando, USA on March 29, 2009. http:// www.clinicaltrialresults.org/slides/AGIR2%20ACC2009%20Bon nefoy.ppt (accessed October 17, 2009).
22. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement: Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-1900.
23. Altman DG, Schulz KF. Statistics notes: Concealing treatment allocation in randomised trials. BMJ 2001; 323: 446-447.
24. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-46.
25. Greenland S. Invited commentary: A critical look at some popular meta-analytic methods. Am J Epidemiol 1994; 140: 290-296.
26. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282: 1054-1060.
27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
31. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
32. Koyanagi R, Hagiwara N, Kasanuki H, Tsurumi Y, Ogawa H; HIJAMI investigators. Primary percutaneous coronary intervention vs conservative treatment for acute ST elevation myocardial infarction: Short- and long-term follow-up according to disease severity. Circ J 2008; 72: 1391-1396.
33. Zhang F, Ge J, Qian J, Fan B, Wang Q, Ge L, et al. Sirolimus-elut-ing stents in real-world patients with ST-segment elevation acute myocardial infarction. Int Heart J 2007; 48: 303-311.
34. Shiraishi J, Kohno Y, Sawada T, Arihara M, Hyogo M, Yagi T, et al. Effects of hospital volume of primary percutaneous coronary interventions on angiographic results and in-hospital outcomes for acute myocardial infarction. Circ J 2008; 72: 1041-1046.
35. Valente S, Lazzeri C, Salvadori C, Chiostri M, Giglioli C, Poli S, et al. Effectiveness and safety of routine primary angioplasty in patients aged > or =85 years with acute myocardial infarction. Circ J 2008; 72: 67-70.
36. Waters RE 2nd, Mahaffey KW, Granger CB, Roe MT. Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. Am Heart J 2003; 146: 958-968.
37. Zijlstra F, Ernst N, de Boer MJ, Nibbering E, Suryapranata H, Hoorntje JC, et al. Infuence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. J Am Coll Cardiol 2002; 39: 1733-1737.
38. Ly HQ, Kirtane AJ, Buros J, Giugliano RP, Popma JJ, Antman EM, et al. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fbrino-lytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol 2005; 95: 383-386.
39. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, et al. Facilitated PCI in patients with ST-elevation myo-cardial infarction. N Engl J Med 2008; 358: 2205-2217.
40. Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffn J, et al. Normal fow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104: 636-641.
41. De Luca G, Ernst N, Zijlstra F, van't Hof AW, Hoorntje JC, Dambrink JH, et al. Preprocedural TIMI fow and mortality in patients with acute myocardial infarction treated by primary angio-plasty. J Am Coll Cardiol 2004; 43: 1363-1367.
42. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, et al. Relationship between patient's risk profle and benefts in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: A meta-regression analysis of randomized trials. J Am Coll Cardiol 2006; 47: 685-486.